Zoetis Inc. or ACADIA Pharmaceuticals Inc.: Who Leads in Yearly Revenue?

Zoetis Inc. vs. ACADIA Pharmaceuticals Inc.: A Revenue Showdown

In the competitive landscape of the pharmaceutical industry, revenue growth is a key indicator of success. Over the past decade, Zoetis Inc. has consistently outperformed ACADIA Pharmaceuticals Inc. in terms of yearly revenue. From 2014 to 2023, Zoetis Inc. saw its revenue grow by approximately 79%, reaching a peak of $8.54 billion in 2023. In contrast, ACADIA Pharmaceuticals Inc. experienced a more modest growth, with revenue increasing from a mere $61,000 in 2015 to $726 million in 2023, marking a significant rise but still trailing behind Zoetis Inc. by a wide margin. This stark difference highlights Zoetis Inc.'s dominant position in the market, driven by its robust product portfolio and strategic market expansions. As the industry evolves, the question remains: Can ACADIA Pharmaceuticals Inc. close the gap, or will Zoetis Inc. continue to lead the charge?